• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

对于年龄相关性黄斑变性(AMD)患者,在经瞳孔温热疗法治疗后,对从最初隐匿性发展为主要为典型性的脉络膜新生血管(CNV)采用维替泊芬进行光动力疗法。

Photodynamic therapy with verteporfin following transpupillary thermotherapy for CNV evolving from an initially occult to a predominantly classic form, in patients with AMD.

作者信息

Hamon F, Goeminne P

机构信息

Clinique Ambroise Pare, Lille, France.

出版信息

Semin Ophthalmol. 2001 Dec;16(4):223-32. doi: 10.1076/soph.16.4.223.10301.

DOI:10.1076/soph.16.4.223.10301
PMID:15513445
Abstract

The purpose of this paper is to evaluate photodynamic therapy (PDT) in the management of choroidal neovascularization (CNV) due to age-related macular degeneration (AMD) that converted from occult CNV to classic CNV after treatment with transpupillary thermotherapy (TTT). One hundred and fifty-four eyes of 130 patients with symptomatic occult CNV were treated between June 2000 and August 2001. We have analyzed data from patients treated with PDT because of a conversion from occult to classic CNV after TTT. The results were that twenty-four of 154 eyes developed a predominantly classic CNV; 20 eyes of 19 consecutive patients were treated with PDT with verteporfin. The mean follow-up period was 10 months. The mean delay for retreatment with TTT was 3 months; 3 eyes initially presented a pure occult CNV, 15 a minimally classic CNV, 1 an occult CNV with pigment epithelial detachment, and 1 a large macular subretinal hemorrhage with a subfoveal focal hot spot. The average classic component within a lesion before TTT was 20%. Recurrence of classic CNV was noted in the first 3 months for 14 eyes. Visual acuity improved in 5 eyes by >/=2 lines, and in 2 eyes by 1 line; 4 of 20 eyes had stabilized visual acuity; 7 eyes had a visual acuity decline of >/=2 lines; 2 eyes lost 1 line. All patients had reduction of metamorphopsia and reduction of exudation; 14 eyes had a little subretinal fibrosis and some partially atrophic areas; 6 eyes had slightly increased leakage in the late phase of the angiogram. In conclusion, association of TTT and PDT appears to be safe and may help practitioners to manage some difficult cases. This study seems to confirm the great efficacy of PDT in CNV with recent activity.

摘要

本文的目的是评估光动力疗法(PDT)在治疗年龄相关性黄斑变性(AMD)所致脉络膜新生血管(CNV)中的作用,这些CNV是经瞳孔温热疗法(TTT)治疗后从隐匿性CNV转变为典型性CNV的。2000年6月至2001年8月期间,对130例有症状的隐匿性CNV患者的154只眼进行了治疗。我们分析了因TTT后从隐匿性转变为典型性CNV而接受PDT治疗的患者的数据。结果显示,154只眼中有24只主要发展为典型性CNV;19例连续患者的20只眼接受了维替泊芬PDT治疗。平均随访期为10个月。TTT再次治疗的平均延迟时间为3个月;3只眼最初表现为单纯隐匿性CNV,15只为轻度典型性CNV,1只为伴有色素上皮脱离的隐匿性CNV,1只为伴有黄斑中心凹下局灶性热点的大片黄斑视网膜下出血。TTT治疗前病变内平均典型成分占20%。14只眼在最初3个月内出现典型性CNV复发。5只眼视力提高≥2行,2只眼提高1行;20只眼中4只眼视力稳定;7只眼视力下降≥2行;2只眼视力下降1行。所有患者的视物变形和渗出均减轻;14只眼有少许视网膜下纤维化和一些部分萎缩区域;6只眼在血管造影晚期渗漏略有增加。总之,TTT与PDT联合应用似乎是安全可行的,可能有助于医生处理一些疑难病例。本研究似乎证实了PDT对近期活动期CNV有显著疗效。

相似文献

1
Photodynamic therapy with verteporfin following transpupillary thermotherapy for CNV evolving from an initially occult to a predominantly classic form, in patients with AMD.对于年龄相关性黄斑变性(AMD)患者,在经瞳孔温热疗法治疗后,对从最初隐匿性发展为主要为典型性的脉络膜新生血管(CNV)采用维替泊芬进行光动力疗法。
Semin Ophthalmol. 2001 Dec;16(4):223-32. doi: 10.1076/soph.16.4.223.10301.
2
Photodynamic therapy of subfoveal choroidal neovascularization in age-related macular degeneration with verteporfin: one-year results of 2 randomized clinical trials--TAP report. Treatment of age-related macular degeneration with photodynamic therapy (TAP) Study Group.维替泊芬光动力疗法治疗年龄相关性黄斑变性的中心凹下脉络膜新生血管:两项随机临床试验的一年结果——TAP报告。年龄相关性黄斑变性光动力疗法(TAP)研究组
Arch Ophthalmol. 1999 Oct;117(10):1329-45.
3
Photodynamic therapy with verteporfin in Belgian patients with subfoveal choroidal neovascularization secondary to age-related macular degeneration.
Bull Soc Belge Ophtalmol. 2006(299):57-64.
4
Verteporfin therapy of subfoveal choroidal neovascularization in patients with age-related macular degeneration: additional information regarding baseline lesion composition's impact on vision outcomes-TAP report No. 3.维替泊芬治疗年龄相关性黄斑变性患者的黄斑中心凹下脉络膜新生血管:关于基线病变组成对视力结果影响的补充信息——TAP报告第3号
Arch Ophthalmol. 2002 Nov;120(11):1443-54. doi: 10.1001/archopht.120.11.1443.
5
Photodynamic therapy of subfoveal choroidal neovascularization in age-related macular degeneration with verteporfin: two-year results of 2 randomized clinical trials-tap report 2.维替泊芬光动力疗法治疗年龄相关性黄斑变性中心凹下脉络膜新生血管:两项随机临床试验的两年结果——TAP报告2
Arch Ophthalmol. 2001 Feb;119(2):198-207.
6
A prospective study on different methods for the treatment of choroidal neovascularization. The efficacy of verteporfin photodynamic therapy, intravitreal bevacizumab and transpupillary thermotherapy in patients with neovascular age-related macular degeneration.一项关于治疗脉络膜新生血管的不同方法的前瞻性研究。光动力疗法、玻璃体内注射贝伐单抗和经瞳孔温热疗法治疗新生血管性年龄相关性黄斑变性的疗效。
Med Sci Monit. 2012 Jun;18(6):CR374-80. doi: 10.12659/msm.882907.
7
Photodynamic therapy with verteporfin for choroidal neovascularization caused by age-related macular degeneration: results of retreatments in a phase 1 and 2 study.维替泊芬光动力疗法治疗年龄相关性黄斑变性引起的脉络膜新生血管:1期和2期研究中的再次治疗结果
Arch Ophthalmol. 1999 Sep;117(9):1177-87. doi: 10.1001/archopht.117.9.1177.
8
12-month retrospective study and review of photodynamic therapy with verteporfin for subfoveal choroidal neovascularization in age-related macular degeneration.一项为期12个月的回顾性研究,对维替泊芬光动力疗法治疗年龄相关性黄斑变性中心凹下脉络膜新生血管进行回顾分析。
Retina. 2008 Feb;28(2):289-97. doi: 10.1097/IAE.0b013e31813ffe90.
9
Verteporfin photodynamic therapy for extrafoveal choroidal neovascularisation secondary to age-related macular degeneration.维替泊芬光动力疗法治疗年龄相关性黄斑变性继发的黄斑中心凹外脉络膜新生血管
Graefes Arch Clin Exp Ophthalmol. 2005 Dec;243(12):1241-6. doi: 10.1007/s00417-005-0021-8. Epub 2005 Jul 12.
10
Verteporfin therapy of subfoveal minimally classic choroidal neovascularization in age-related macular degeneration: 2-year results of a randomized clinical trial.维替泊芬治疗年龄相关性黄斑变性中黄斑中心凹下轻度典型脉络膜新生血管:一项随机临床试验的2年结果
Arch Ophthalmol. 2005 Apr;123(4):448-57. doi: 10.1001/archopht.123.4.448.